Some good news for the UK industry in turbulent times is always welcome, and several announcement this month showed us why the biotech sector in the country is looking extremely promising g
Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline.
‘Man flu’ is real, according to an exclusive trial carried out by pharmaphorum and based on a new methodology that could revolutionise research into some of the world’s most challenging dis